Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatment
WIREs Mechanisms of Disease · 2022-11 · 14 (6)
DOI: 10.1002/wsbm.1576 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Mechanisms of Disease, online erschienen am 24.07.2022. Verfasst von Tianning Gu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neurotoxicity Syndromes, Neoplasms. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Chimeric antigen receptor T‐cell (CAR‐T) treatment has revolutionized the landscape of cancer therapy with significant efficacy on hematologic malignancy, especially in relapsed and refractory B cell malignancies. However, unexpected serious toxicities such as cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) still hamper its broad application. Clinical trials using CAR‐T cells targeting specific antigens on tumor cell surface have provided valuable information about the characteristics of ICANS. With unclear mechanism of ICANS after CAR‐T treatment, unremitting efforts have been devoted to further exploration. Clinical findings from patients with ICANS strongly indicated existence of overactivated peripheral immune response followed by endothelial activation‐induced blood–brain barrier (BBB) dysfunction, which triggers subsequent central nervous system (CNS) inflammation and neurotoxicity. Several animal models have been built but failed to fully replicate the whole spectrum of ICANS in human. Hopefully, novel and powerful technologies like single‐cell analysis may help decipher the precise cellular response within CNS from a different perspective when ICANS happens. Moreover, multidisciplinary cooperation among the subjects of immunology, hematology, and neurology will facilitate better understanding about the complex immune interaction between the peripheral, protective barriers, and CNS in ICANS. This review elaborates recent findings about ICANS after CAR‐T treatment from bed to bench, and discusses the potential cellular and molecular mechanisms that may promote effective management in the future. This article is categorized under: Cancer > Biomedical Engineering Immune System Diseases > Molecular and Cellular Physiology Neurological Diseases > Molecular and Cellular Physiology
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China.
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
- Institute of Hematology, Zhejiang University, Hangzhou, 310058, China.
- Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.
ORCID-Profile: Tianning Gu, Yongxian Hu, He Huang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Gu, T., Hu, K., Si, X., Hu, Y., & Huang, H. (2022). Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatment. WIREs Mechanisms of Disease, 14(6). https://doi.org/10.1002/wsbm.1576
Vancouver
Gu T, Hu K, Si X, Hu Y, Huang H. Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatment. WIREs Mechanisms of Disease. 2022;14(6). doi:10.1002/wsbm.1576
BibTeX
@article{Gu2022,
author = {Gu, Tianning and Hu, Kejia and Si, Xiaohui and Hu, Yongxian and Huang, He},
title = {Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatment},
journal = {WIREs Mechanisms of Disease},
year = {2022},
volume = {14},
number = {6},
doi = {10.1002/wsbm.1576}
}
EUVIMED